Novel immunotherapeutic strategies in development for renal cell carcinoma

European Urology

Volumn 63, Issue 5, 2013, Pages 881-889

  Inman, Brant A ^a   Harrison, Michael R ^a   George, Daniel J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antitumor activity; Cytotoxic T lymphocyte antigen 4; Immunotherapy; Interferon alpha; Interleukin 2; Nephrectomy; Programmed death 1; Renal cell cancer; Vaccine; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; DENILEUKIN DIFTITOX; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PAZOPANIB; SUNITINIB; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTINUOUS INFUSION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG SAFETY; FOLLOW UP; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; REVIEW; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84876019889     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.10.006     Document Type: Review

References (60)

1. K. Gupta, J.D. Miller, J.Z. Li, M.W. Russell, and C. Charbonneau Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 2008 193 205
2. T.M. De Reijke, J. Bellmunt, H. van Poppel, S. Marreaud, and M. Aapro EORTC-GU group expert opinion on metastatic renal cell cancer Eur J Cancer 45 2009 765 773
3. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
4. A.J. Scherr, J.P. Lima, E.C. Sasse, C.S. Lima, and A.D. Sasse Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis BMC Cancer 11 2011 115
5. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Kidney cancer, version 2.2011 2011 National Comprehensive Cancer Network, Inc. Fort Washington, PA
6. J.A. Klapper, S.G. Downey, and F.O. Smith High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006 Cancer 113 2008 293 301
7. S.A. Rosenberg, M.T. Lotze, and J.C. Yang Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer J Natl Cancer Inst 21 1993 622 632
8. D.F. McDermott, M.M. Regan, and J.I. Clark Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141
9. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
10. B. Escudier, and V. Kataja Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl 5 2010 v137 v139
11. C. Coppin, L. Le, F. Porzsolt, and T. Wilt Targeted therapy for advanced renal cell carcinoma Cochrane Database Syst Rev 2008 CD006017
12. L. Albiges, S. Oudard, and S. Negrier Complete remission with tyrosine kinase inhibitors in renal cell carcinoma J Clin Oncol 30 2012 482 487
13. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
14. J.C. Yang, M. Hughes, and U. Kammula Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
15. R.J. Motzer, M. Mazumdar, and J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
16. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
17. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
18. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
19. B.I. Rini, and K. Flaherty Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma Urol Oncol 26 2008 543 549
20. A. Di Napoli, and S. Signoretti Tissue biomarkers in renal cell carcinoma: issues and solutions Cancer 115 10 Suppl 2009 2290 2297
21. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
22. T.F. Gajewski, Y. Meng, and H. Harlin Chemokines expressed in melanoma metastases associated with T-cell infiltration [abstract 8501] J Clin Oncol 25 18s 2007
23. T.F. Gajewski, Y. Zha, and B. Thurner Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine [abstract 9002] J Clin Oncol 27 15s 2009
24. J. Louahed, O. Gruselle, and S. Gaulis Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients [abstract 9045] J Clin Oncol 26 Suppl 2008
25. J.F. Vansteenkiste, M. Zielinski, and I.J. Dahabreh Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC) [abstract 7501] J Clin Oncol 26 Suppl 2008
26. R.J. Sullivan, Y. Hoshida, and J. Brunet A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response [abstract 9003] J Clin Oncol 27 15s 2009
27. O. Hamid, S.D. Chasalow, and Z. Tsuchihashi Association of baseline and on-study tumor biopsy markers with clinical activity in patients with advanced melanoma treated with ipilimumab [abstract 9008] J Clin Oncol 27 15s 2009
28. M.M. Elhilali, M. Gleave, and Y. Fradet Placebo-associated remissions in a multicentre, randomized, double-blind trial of gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group BJU Int 86 2000 613 618
29. T. Schwaab, A. Schwarzer, and B. Wolf Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients Clin Cancer Res 15 2009 4986 4992
30. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
31. J. Wierecky, M.R. Muller, and S. Wirths Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients Cancer Res 66 2006 5910 5918
32. A. Draube, N. Klein-Gonzalez, and S. Mattheus Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis PLoS One 6 2011 e18801
33. L. Gommersall, D. Hayne, C. Lynch, J.V. Joseph, M. Arya, and H.R. Patel Allogeneic stem-cell transplantation for renal-cell cancer Lancet Oncol 5 2004 561 567
34. P. Sharma, and C. Logothetis Prostate cancer: combination of vaccine plus ipilimumab-safety and toxicity Nat Rev Urol 9 2012 302 303
35. R.H. Thompson, H. Dong, and C.M. Lohse PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin Cancer Res 13 2007 1757 1761
36. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
37. D.F. McDermott, C.G. Drake, and M. Sznol Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma [abstract 4505] J Clin Oncol 30 Suppl 2012
38. Search results for BMS-936558. Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/results?term=BMS-936558&Search=Search.
39. R.H. Thompson, S.M. Kuntz, and B.C. Leibovich Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
40. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
41. P. Attia, A.V. Maker, L.R. Haworth, L. Rogers-Freezer, and S.A. Rosenberg Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma J Immunother 28 2005 582 592
42. E. Atchison, J. Eklund, and B. Martone A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC) J Immunother 33 2010 716 722
43. C. Casati, C. Camisaschi, and F. Rini Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity Cancer Res 66 2006 4450 4460
44. C. Brignone, B. Escudier, C. Grygar, M. Marcu, and F. Triebel A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma Clin Cancer Res 15 2009 6225 6231
45. D. Rüttinger, H. Winter, and N.K. van den Engel Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference Oncologist 15 2010 112 118
46. J.W. Simons, E.M. Jaffee, and C.E. Weber Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537 1546
47. M. Fishman, T.B. Hunter, and H. Soliman Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma J Immunother 31 2008 72 80
48. S.J. Antonia, J. Seigne, and J. Diaz Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma J Urol 167 2002 1995 2000
49. J. Rosenblatt, and D.F. McDermott Immunotherapy for renal cell carcinoma Hematol Oncol Clin North Am 25 2011 793 812
50. A. Flörcken, J. Kopp, and K. Movassaghi Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): final analysis of a clinical phase I/II study [abstract e15053] J Clin Oncol 30 Suppl 2012
51. C. Wood, P. Srivastava, and R. Bukowski An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 2008 145 154
52. Reinhardt C, Zdrojowy R, Szczylik C, et al. Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC) [abstract 4529]. Poster presented at: American Society of Clinical Oncology; June 2010; Chicago, IL, USA.
53. I.D. Davis, Z. Liu, and W. Saunders A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma Cancer Immun 7 2007 14
54. I.D. Davis, G.A. Wiseman, and F.T. Lee A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma Cancer Immun 7 2007 13
55. N.T. Ueno, and Y.C. Cheng The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy Bone Marrow Transplant 38 2006 711 714
56. M. Bregni, F. Ciceri, and J. Peccatori Allogeneic stem cell transplantation for metastatic renal cell cancer (RCC) J Cancer 2 2011 347 349
57. Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ). Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00720941.
58. R. Figlin, C.A. Nicolette, and A. Amin Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib [abstract 2532] J Clin Oncol 29 suppl 2011
59. R.A. Figlin, A. Amin, A. Dudek AGS-003-006 Study Group Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC) [abstract 348] J Clin Oncol 30 Suppl 5 2012
60. Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT). Clinicaltrials.gov. Web site. http://www.clinicaltrials.gov/ct2/show/ NCT01582672?term=NCT01582672&rank=1.